Heron Therapeutics, Inc.
Here’s whether Heron Therapeutics, Inc. (HRTX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-2.78% over 10 days); RSI 18 — oversold; weak 1-year return of -78.6%; 3-month momentum negative (-57.1%); rising volume on a downtrend (distribution, 1.49x avg). Currently 81.4% off its 52-week high. Score: -7/7.
HRTX is trading below its 200-day MA ($1.15) — a key warning sign the longer-term trend is under pressure. An RSI of 18.4 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -78.6% compares to +24.4% for SPY (trailed the market by 103.0%). The current 81.4% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.